CRVO
CervoMed Inc. NASDAQ$3.70
Mkt Cap $34.3M
52w Low $3.51
2.0% of range
52w High $13.13
50d MA $4.08
200d MA $6.98
P/E (TTM)
-1.2x
EV/EBITDA
-2.2x
P/B
1.8x
Debt/Equity
0.0x
ROE
-148.0%
P/FCF
-3.0x
RSI (14)
—
ATR (14)
—
Beta
-5.04
50d MA
$4.08
200d MA
$6.98
Avg Volume
75.3K
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | AMC | -0.79 | -0.88 | -11.4% | 4.25 | +0.5% | +1.4% | +6.6% | -0.2% | -0.5% | -5.4% | — |
| Nov 7, 2025 | AMC | -0.68 | -0.84 | -23.5% | 6.92 | -2.3% | -0.3% | +0.7% | +7.1% | +4.8% | +11.0% | — |
| Aug 8, 2025 | AMC | -0.57 | -0.70 | -22.8% | 9.85 | +1.1% | -3.6% | -4.6% | -2.1% | +3.5% | +2.7% | — |
| May 12, 2025 | AMC | -0.60 | -0.56 | +6.7% | 9.10 | -2.6% | -4.4% | -8.6% | -5.1% | -3.5% | -3.4% | — |
| Mar 17, 2025 | AMC | -0.67 | -0.80 | -19.4% | 9.05 | +7.5% | +3.2% | +3.5% | +27.7% | +57.9% | +18.3% | — |
| Nov 12, 2024 | AMC | -0.41 | -0.55 | -34.1% | 11.83 | +1.0% | -5.2% | -7.7% | -9.0% | -12.0% | -14.8% | — |
| Aug 9, 2024 | AMC | -0.24 | -0.27 | -12.5% | 11.28 | -3.9% | +7.5% | +33.0% | +51.1% | +51.1% | +61.9% | — |
| May 14, 2024 | AMC | -0.46 | -0.41 | +10.9% | 24.70 | +3.9% | +0.1% | -1.4% | -2.5% | -20.1% | -21.3% | — |
| Mar 25, 2024 | AMC | -0.29 | -0.38 | -31.0% | 21.08 | +2.5% | -1.4% | -6.9% | +10.5% | +7.7% | +5.1% | — |
| Nov 13, 2023 | AMC | -0.95 | -0.70 | +26.3% | 9.73 | +0.3% | -1.4% | +1.6% | +1.3% | +1.4% | +0.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $3.96 | +0.5% | -2.3% | -1.5% | -3.0% | -5.8% | -7.4% |
| Apr 22 | D. Boral Capital | Maintains | Buy → Buy | — | $3.89 | $4.00 | +2.8% | +1.3% | -1.0% | -0.3% | -1.8% | -4.6% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $3.84 | $3.90 | +1.6% | +5.2% | +4.9% | -0.3% | +4.4% | +5.2% |
| Mar 19 | D. Boral Capital | Maintains | Buy → Buy | — | $4.24 | $4.23 | -0.2% | -0.2% | -5.2% | -5.2% | -7.5% | -4.7% |
| Mar 18 | Roth Capital | Maintains | Buy → Buy | — | $4.53 | $4.55 | +0.4% | -6.4% | -6.6% | -11.3% | -11.3% | -13.5% |
| Mar 18 | Chardan Capital | Maintains | Buy → Buy | — | $4.53 | $4.55 | +0.4% | -6.4% | -6.6% | -11.3% | -11.3% | -13.5% |
| Mar 16 | D. Boral Capital | Maintains | Buy → Buy | — | $4.25 | $4.27 | +0.5% | +1.4% | +6.6% | -0.2% | -0.5% | -5.4% |
| Mar 5 | Chardan Capital | Maintains | Buy → Buy | — | $4.02 | $4.07 | +1.2% | -0.2% | +2.2% | +12.9% | +20.9% | +10.0% |
| Mar 4 | D. Boral Capital | Maintains | Buy → Buy | — | $4.01 | $4.23 | +5.5% | +0.2% | +0.0% | +2.5% | +13.2% | +21.2% |
| Feb 18 | D. Boral Capital | Maintains | Buy → Buy | — | $4.54 | $4.75 | +4.6% | +8.6% | +15.2% | +2.0% | +2.2% | +5.5% |
Recent Filings
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed presented clinical data at the American Academy of Neurology conference, incorporating key findings into its SEC filing to highlight potentially significant trial results for investors.
Apr 22
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CervoMed's presentation of positive neflamapimod clinical findings and finalized Phase 3 trial design signals advancement toward a potentially valuable dementia treatment, which could drive stock appreciation if trial results prove successful.
Apr 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Crescent Robotics disclosed information via Regulation FD that isn't legally binding and won't affect existing SEC filings, so investors should disregard this as non-material disclosure.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CRVO's biomarker analysis showing stronger treatment effects in lower tau patients could support a narrower, higher-probability approval pathway, potentially de-risking future regulatory decisions and improving stock valuation.
Mar 19
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cerevel Therapeutics disclosed material non-public information to select parties, potentially signaling upcoming news that could impact stock valuation before public announcement.
Mar 17
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed's incorporation of its March 4, 2026 press release details into an 8-K filing indicates a material corporate event requiring SEC disclosure, though the specific announcement details require reviewing the referenced press release.
Mar 4
8-K · 8.01
!! High
CervoMed Inc. -- 8-K 8.01: Material Event / Announcement
CervoMed Inc. disclosed material information through a February 18, 2026 press release, incorporated into this 8-K filing, though specific details require reviewing the referenced press release for investor impact assessment.
Feb 18
Data updated apr 25, 2026 3:24am
· Source: massive.com